{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062936","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.053507+00:00","generated_at":"2026-06-08T05:15:45.406763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials","bullets":["Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).","Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.","Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).","CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.","Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062936","json":"https://secwatch.observer/filing/0000950170-23-062936.json","markdown":"https://secwatch.observer/filing/0000950170-23-062936.md","text":"https://secwatch.observer/filing/0000950170-23-062936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/0000950170-23-062936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/sprb-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:15:45.406763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d20c43158b3bfc589a8d3374e436a18f0d9f7662","claim":"SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income $12.4 million.","evidence_excerpt":"Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/0000950170-23-062936-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$12.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}